The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

The recent development of in vitro hepatitis C virus (HCV) RNA replication systems has provided useful tools for studying the intracellular anti-HCV activity of ribavirin. Ribavirin has been shown to: (1) induce "error catastrophe" in poliovirus, Proc. Natl. Acad. Sci. USA 98, 6895-6900), (2) be a pseudo-substrate of the HCV RNA-dependent RNA polymerase (RdRp) in vitro, J. Biol. Chem. 276, 46094-46098), and (3) increase mutations in HCV RNA in the binary T7 polymerase/HCV cDNA replication system, J. Virol. 76, 8505-8517). These findings have led to the hypothesis that ribavirin may also induce error catastrophe in HCV. However, the functional relevance of ribavirin-induced HCV RNA mutagenesis is unclear. By use of a colony formation assay, in which RNA is isolated from the HCV subgenomic replicon system following treatment, the impact of ribavirin, inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors, and the combination was assessed. Ribavirin reduced HCV replicon colony-forming efficiency (CFE) in a dose-dependent fashion, suggesting that ribavirin may be misincorporated into replicon RNA and result in an anti-replicon effect analogous to error catastrophe. This effect was markedly suppressed by addition of exogenous guanosine. Combination treatment with ribavirin and mycophenolic acid (MPA) or VX-497, both potent, nonnucleoside IMPDH inhibitors, led to a greatly enhanced anti-replicon effect. This enhancement was reversed by inclusion of guanosine with the treatment. In contrast, MPA or VX-497 alone had only marginal effects on both the quantity and quality (CFE) of replicon RNA, suggesting that although IMPDH inhibition is an important contributing factor to the overall ribavirin anti-HCV replicon activity, IMPDH inhibition by itself is not sufficient to exert an anti-HCV effect. Sequencing data targeting the neo gene segment of the HCV replicon indicated that ribavirin together with MPA or VX-497 increased the replicon error rate by about two-fold. Taken together these results further suggest that lethal mutagenesis may be an effective anti-HCV strategy. The colony formation assay provides a useful tool for evaluating mutagenic nucleoside analogs for HCV therapy. Finally, the data from combination treatment indicate potential therapeutic value for an enhanced anti-HCV effect when using ribavirin in combination with IMPDH inhibition.

[1]  C. Dash,et al.  Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. , 1998, British journal of clinical pharmacology.

[2]  C. Cameron,et al.  Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin* , 2001, The Journal of Biological Chemistry.

[3]  L. Philipson,et al.  Inhibition of Influenza Virus Ribonucleic Acid Polymerase by Ribavirin Triphosphate , 1977, Antimicrobial Agents and Chemotherapy.

[4]  E. De Clercq,et al.  Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds , 1991, Antimicrobial Agents and Chemotherapy.

[5]  E. Domingo,et al.  Efficient Virus Extinction by Combinations of a Mutagen and Antiviral Inhibitors , 2001, Journal of Virology.

[6]  F. Kayser,et al.  Transferable Plasmids Mediating Multiple-Antibiotic Resistance in Streptococcus faecalis subsp. liquefaciens , 1977, Antimicrobial Agents and Chemotherapy.

[7]  R. K. Robins,et al.  Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide , 1972, Science.

[8]  J. Patterson,et al.  Mechanism of La Crosse virus inhibition by ribavirin , 1989, Antimicrobial Agents and Chemotherapy.

[9]  C. Rice,et al.  Efficient initiation of HCV RNA replication in cell culture. , 2000, Science.

[10]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[11]  H. Thomas,et al.  Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. , 1996, Journal of hepatology.

[12]  R. Lanford,et al.  Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes , 2001, Journal of Virology.

[13]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[14]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[15]  Z. Hong,et al.  Mechanisms of Action of Ribavirin in Antiviral Therapies , 2001, Antiviral chemistry & chemotherapy.

[16]  C. Cameron,et al.  The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase , 2001, Current opinion in infectious diseases.

[17]  R. J. Bauer,et al.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Silver,et al.  Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line , 1999 .

[19]  J. B. Antczak,et al.  Studies on the mechanism of the antiviral activity of ribavirin against reovirus. , 1989, Virology.

[20]  B. Kommerell,et al.  Hepatitis C virus replication. , 1992, The New England journal of medicine.

[21]  J. Mullins,et al.  Lethal mutagenesis of HIV with mutagenic nucleoside analogs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Schmidt,et al.  Viral RNA Mutations Are Region Specific and Increased by Ribavirin in a Full-Length Hepatitis C Virus Replication System , 2002, Journal of Virology.

[23]  P. Glue,et al.  The clinical pharmacology of ribavirin. , 1999, Seminars in liver disease.

[24]  M. Eigen Selforganization of matter and the evolution of biological macromolecules , 1971, Naturwissenschaften.

[25]  H J Alter,et al.  Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.

[26]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[27]  K. O'connell,et al.  Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription , 1988, Antimicrobial Agents and Chemotherapy.

[28]  J. Patterson,et al.  Mechanism of action of ribavirin , 1991 .

[29]  R. Bartenschlager,et al.  Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations , 2001, Journal of Virology.

[30]  M. Alter,et al.  Epidemiology of Hepatitis C , 2018, Clinical liver disease.

[31]  David A. Steinhauer,et al.  Mutation Frequencies at Defined Single Codon Sites in Vesicular Stomatitis Virus and Poliovirus Can Be Increased Only Slightly by Chemical Mutagenesis , 1990, Journal of virology.

[32]  V. Stollar,et al.  Inhibitors of IMP dehydrogenase prevent sindbis virus replication and reduce GTP levels in Aedes albopictus cells. , 1981, Virology.

[33]  R. Bartenschlager,et al.  Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs , 2001, Journal of Virology.

[34]  V. Knight,et al.  Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. , 1985, Antiviral research.

[35]  Reyes Gr Ribavirin: recent insights into antiviral mechanisms of action. , 2001 .

[36]  P. McNamara,et al.  Pharmacokinetics and Absolute Bioavailability of Ribavirin in Healthy Volunteers as Determined by Stable-Isotope Methodology , 1999, Antimicrobial Agents and Chemotherapy.

[37]  Y. Natsumeda,et al.  Characterization of human type I and type II IMP dehydrogenases. , 1993, The Journal of biological chemistry.

[38]  Pedro R. Lowenstein,et al.  Response of Foot-and-Mouth Disease Virus to Increased Mutagenesis: Influence of Viral Load and Fitness in Loss of Infectivity , 2000, Journal of Virology.

[39]  G. Davis,et al.  Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial , 1997, Hepatology.

[40]  C. Cameron,et al.  RNA virus error catastrophe: Direct molecular test by using ribavirin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  E. Domingo,et al.  Molecular indetermination in the transition to error catastrophe: Systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Walker,et al.  Hepatitis C virus infection. , 2001, The New England journal of medicine.

[43]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.

[44]  J. Arnold,et al.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen , 2000, Nature Medicine.

[45]  E. Domingo,et al.  Viruses at the edge of adaptation. , 2000, Virology.

[46]  R. Xavier,et al.  Hepatitis C virus replication is directly inhibited by IFN-α in a full-length binary expression system , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Reyes Ribavirin: recent insights into antiviral mechanisms of action. , 2001, Current opinion in drug discovery & development.

[48]  A. Kwong,et al.  Broad-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: a Comparison with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon , 2000, Antimicrobial Agents and Chemotherapy.

[49]  Deborah Chavez,et al.  Antiviral Effect and Virus-Host Interactions in Response to Alpha Interferon, Gamma Interferon, Poly(I)-Poly(C), Tumor Necrosis Factor Alpha, and Ribavirin in Hepatitis C Virus Subgenomic Replicons , 2003, Journal of Virology.